gdc
SABCS 2020 Wrap-Up

Getting Inside Breast Cancer

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, discusses the importance of ENHERTU to patients with HER2-positive breast cancer.
Conference Correspondent – December 14, 2020
Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Breast Nurse Navigator
Novant Health: Derrick L. Davis Cancer Center
Winston-Salem, NC
Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, discusses the importance of ENHERTU to patients with HER2-positive breast cancer.

Share this:

Recommended For You
SABCS 2020 Wrap-Up
Updated Results from the DESTINY-Breast01 Study
A phase 2 trial of Enhertu (trastuzumab deruxtecan) in patients with HER2-positive metastatic breast cancer show high rates of positive results in patients who have been heavily pretreated. These results are preliminary and encouraging.
SABCS 2020 Wrap-Up
Researching the Effect of Breast Cancer on Body Image and Sexual Health
Breast cancer and its treatment impacts sexual health, which is an important topic for patients and clinicians to be able to address throughout the treatment process.
SABCS 2020 Wrap-Up
Enhertu Compared with Kadcyla in Patients with HER2-Positive, Residual Invasive Early Breast Cancer After Neoadjuvant Therapy
The DESTINY-Breast05 trial will help researchers understand the potential benefit of Enhertu (trastuzumab deruxtecan), a powerful potential treatment of patients with breast cancer with residual invasive disease after receiving chemotherapy.
SABCS 2020 Wrap-Up
Examining the Impact on Breast Cancer Treatment During COVID-19
Panelists discuss the challenges of the pandemic and its impact on the risk for pandemic-related disruptions in cancer care, breast cancer diagnosis, timing and choice of treatment, and mental health.
Last modified: December 14, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country